Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 28;320(8):815-824.
doi: 10.1001/jama.2018.11406.

Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review

Affiliations
Review

Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review

Henry R Kranzler et al. JAMA. .

Abstract

Importance: Alcohol consumption is associated with 88 000 US deaths annually. Although routine screening for heavy alcohol use can identify patients with alcohol use disorder (AUD) and has been recommended, only 1 in 6 US adults report ever having been asked by a health professional about their drinking behavior. Alcohol use disorder, a problematic pattern of alcohol use accompanied by clinically significant impairment or distress, is present in up to 14% of US adults during a 1-year period, although only about 8% of affected individuals are treated in an alcohol treatment facility.

Observations: Four medications are approved by the US Food and Drug Administration to treat AUD: disulfiram, naltrexone (oral and long-acting injectable formulations), and acamprosate. However, patients with AUD most commonly receive counseling. Medications are prescribed to less than 9% of patients who are likely to benefit from them, given evidence that they exert clinically meaningful effects and their inclusion in clinical practice guidelines as first-line treatments for moderate to severe AUD. Naltrexone, which can be given once daily, reduces the likelihood of a return to any drinking by 5% and binge-drinking risk by 10%. Randomized clinical trials also show that some medications approved for other indications, including seizure disorder (eg, topiramate), are efficacious in treating AUD. Currently, there is not sufficient evidence to support the use of pharmacogenetics to personalize AUD treatments.

Conclusions and relevance: Alcohol consumption is associated with a high rate of morbidity and mortality, and heavy alcohol use is the major risk factor for AUD. Simple, valid screening methods can be used to identify patients with heavy alcohol use, who can then be evaluated for the presence of an AUD. Patients receiving a diagnosis of the disorder should be given brief counseling and prescribed a first-line medication (eg, naltrexone) or referred for a more intensive psychosocial intervention.

PubMed Disclaimer

Comment in

Similar articles

Cited by

References

    1. Center for Behavioral Health Statistics and Quality. 2016 National Survey on Drug Use and Health: Detailed Tables Substance Abuse and Mental Health Services Administration, Rockville, MD, 2017. Retrieved from: https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH.... Accessed June 16, 2018.
    1. Centers for Disease Control and Prevention (CDC). 2013. Alcohol and public health: Alcohol-related disease impact (ARDI). Average for United States 2006–2010 alcohol-attributable deaths due to excessive alcohol use. Available at: https://nccd.cdc.gov/DPH_ARDI/Default/Report.aspx?T=AAM&P=f6d7eda7-036e-.... Accessed April 19, 2018.
    1. Centers for Disease Control and Prevention. Excessive drinking is draining the U.S. economy. Centers for Disease Control and Prevention; 2016. Available at: https://www.cdc.gov/features/costsofdrinking/index.html. Accessed April 19, 2018.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing, 2013.
    1. Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder: Results from the national epidemiologic survey on alcohol and related conditions III. JAMA Psychiatry. 2015;72(8):757–66. REPLACE WITH GRANT ET AL. 2017? - PMC - PubMed

Publication types